Blood eosinophil count correlates with severity of respiratory failure in life‐threatening asthma and predicts risk of subsequent exacerbations

An elevated blood eosinophil count when asthma is stable predicts exacerbations and therapeutic response to corticosteroids or biologics targeting eosinophils. Few studies have examined the prognostic value of blood eosinophils measured at exacerbation.

[1]  I. Pavord,et al.  Exacerbations of severe asthma in patients treated with mepolizumab , 2018, European Respiratory Journal.

[2]  E. Bel,et al.  Diagnosing persistent blood eosinophilia in asthma with single blood eosinophil or exhaled nitric oxide level. , 2018, Respiratory medicine.

[3]  M. Weatherall,et al.  Change in biomarkers of type-2 inflammation following severe exacerbations of asthma , 2018, Thorax.

[4]  J. Carreira,et al.  Association between blood eosinophil count with asthma hospital readmissions. , 2018, European journal of internal medicine.

[5]  I. Pavord,et al.  Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.

[6]  K. Rabe,et al.  Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma , 2018, The New England journal of medicine.

[7]  James R. Brown,et al.  Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations , 2018, Thorax.

[8]  P. Gibson.  Variability of blood eosinophils as a biomarker in asthma and COPD , 2018, Respirology.

[9]  M. Kraft,et al.  Eosinophilic and Noneosinophilic Asthma , 2018, American journal of respiratory and critical care medicine.

[10]  A. HoldenKarl,et al.  Comparison of Blood Eosinophil Numbers Between Acute Asthma and Stable Disease in Children with Preschool Wheeze , 2017 .

[11]  M. Weatherall,et al.  Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993–2012) , 2017, The Lancet.

[12]  I. Hirsch,et al.  The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies , 2017, Current medical research and opinion.

[13]  I. Pavord,et al.  Severe eosinophilic asthma: a roadmap to consensus , 2017, European Respiratory Journal.

[14]  P. Sterk,et al.  Long‐term future risk of severe exacerbations: Distinct 5‐year trajectories of problematic asthma , 2017, Allergy.

[15]  B. Nordestgaard,et al.  Association of Blood Eosinophil and Blood Neutrophil Counts with Asthma Exacerbations in the Copenhagen General Population Study. , 2017, Clinical chemistry.

[16]  Anand A. Dalal,et al.  Blood Eosinophil Count and Outcomes in Severe Uncontrolled Asthma: A Prospective Study. , 2017, The journal of allergy and clinical immunology. In practice.

[17]  J. Hirschhorn,et al.  Omalizumab Is Associated with Reduced Acute Severity of Rhinovirus-triggered Asthma Exacerbation. , 2016, American journal of respiratory and critical care medicine.

[18]  E. Bleecker,et al.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.

[19]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[20]  J. Corren,et al.  Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts. , 2016, Chest.

[21]  Christopher E Brightling,et al.  Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. , 2016, The Lancet. Respiratory medicine.

[22]  Mike Thomas,et al.  Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. , 2015, The Lancet. Respiratory medicine.

[23]  H. Ortega,et al.  Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma. , 2015, The Journal of allergy and clinical immunology.

[24]  C. Camargo,et al.  Prevalence of eosinophilia in hospitalized patients with asthma exacerbation. , 2015, Respiratory medicine.

[25]  S. Fowler,et al.  High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma. , 2015, The Journal of allergy and clinical immunology.

[26]  R. Silverman,et al.  A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma. , 2015, The American journal of emergency medicine.

[27]  R. Lutter,et al.  External validation of blood eosinophils, FENO and serum periostin as surrogates for sputum eosinophils in asthma , 2014, Thorax.

[28]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[29]  R. Louis,et al.  Importance of concomitant local and systemic eosinophilia in uncontrolled asthma , 2014, European Respiratory Journal.

[30]  H. Ortega,et al.  Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. , 2013, Annals of the American Thoracic Society.

[31]  British guideline on the management of asthma. , 2014, Thorax.

[32]  C. Janson,et al.  Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. , 2013, The Journal of allergy and clinical immunology.

[33]  E. Bleecker,et al.  Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. , 2013, The Journal of allergy and clinical immunology.

[34]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[35]  R. Hyzy,et al.  Slow-onset asthma deaths have more eosinophils and health care utilization than rapid-onset deaths. , 2008, Respiratory medicine.

[36]  Martyn R Partridge,et al.  British Guideline on the Management of Asthma , 2008, Thorax.

[37]  E. R. Mcfadden,et al.  Acute severe asthma. , 2003, American journal of respiratory and critical care medicine.

[38]  I. Pavord,et al.  Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial , 2000, The Lancet.

[39]  C E Reed,et al.  Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? , 1993, The American review of respiratory disease.

[40]  F. Saulnier,et al.  Long-term prognosis of near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma. , 1992, The American review of respiratory disease.

[41]  Arthur S Slutsky,et al.  Respiratory arrest in near-fatal asthma. , 1991, The New England journal of medicine.

[42]  D. K. Jones,et al.  Comparison of whole-blood eosinophil counts in extrinsic asthmatics with acute and chronic asthma. , 1982, British medical journal.

[43]  D. L. Unger.  ACUTE SEVERE ASTHMA , 1981, The Lancet.